Back to search

Boston University

Rho kinase inhibitors for the treatment of glaucoma

Abstract

dc:description.abstract

Glaucoma is a degenerative disease that contributes greatly to vision loss and blindness worldwide. There are several treatments that focus on alleviating its symptoms, but few address the underlying pathophysiology, the blockage of aqueous outflow, and the onset of neuroretinal damage. Novel drugs under investigation have aimed to address this deficiency. Two of these Rho kinase inhibitors have been approved by national health agencies, and several are in clinical trials. This work investigates the promise of inhibitors of the Rho kinase signaling pathway to treat primary open-angle glaucoma.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bekui, Seli
Advisors dc:contributor.advisor
  • Taylor, Andrew W.
  • Offner, Gwynneth D.
ORCID dc:identifier.orcid

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/49451

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bekui, Seli. Rho kinase inhibitors for the treatment of glaucoma. masters thesis, Boston University, 2023. https://hdl.handle.net/2144/49451